If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 426.30
Bid: 426.10
Ask: 426.40
Change: 5.70 (1.36%)
Spread: 0.30 (0.07%)
Open: 422.00
High: 428.60
Low: 422.00
Prev. Close: 420.60
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

5 Nov 2015 07:00

RNS Number : 6149E
Rentokil Initial PLC
05 November 2015
 



  

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER (Q3) TRADING UPDATE

5 November 2015

 

Results

Q3 2015

Growth

YTD 2015

Growth

£m

AER

AER

CER

AER

AER

CER

Revenue

438.0

(0.4%)

4.1%

1,293.3

-

4.3%

Revenue - ongoing operations1

436.2

0.3%

4.8%

1,287.2

0.7%

5.1%

 

 

Overview (CER)Revenue from ongoing operations increased by 4.8% in the quarter. Q3 organic revenue growth was in line with the second quarter at 1.4% with 3.4% growth from acquisitions. Growth in the Emerging (+11.1%) and Growth (+9.3%) quadrants was strong, with revenue in the Protect and Enhance (-1.4%) and Manage for Value (-4.7%) quadrants down on last year. Revenue from ongoing operations for the nine months ended 30 September 2015 ("year-to-date") increased by 5.1% with organic growth of 1.7% and 3.4% from acquisitions.

Performance continues to be strong in the UK, North America, Asia, Pacific and Latin America driven by continued strong growth in pest control. While conditions remain difficult in France and the Netherlands, year-to-date ongoing revenue in the Europe region is in line with last year.

Cash flowYear-to-date operating and free cash flow are ahead of the prior year and we are confident of delivering free cash flow for the year in excess of £100m.

M&AIn Q3 we acquired five businesses, all in pest control in our Emerging and Growth quadrants. Combined annual revenues of the businesses acquired totalled £17m in the 12 months immediately prior to acquisition. Year-to-date we have acquired 19 businesses with combined annual revenues of £38m. As previously announced our acquisition of The Steritech Group Inc completed on 2nd October and the process of integration is underway and on track.

Commenting on trading in Q3, Andy Ransom, CEO of Rentokil Initial plc, said:"We continue to execute our strategy at pace with the recent acquisition of Steritech providing us with a high quality business with national scale in a key growth market. The performance in the majority of the group continues to be strong although trading in Europe, France in particular, remains challenging. Our guidance for the full year is unchanged."

 

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

01276 536585 / 07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

 

AER - actual exchange rates; CER - constant 2014 exchange rates

 

1ongoing revenue excludes the financial performance of disposed and closed businesses but includes results from acquisitions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMGMNDRGKZM
Date   Source Headline
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.